NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up

EP: 1.Assessing Risk in NMIBC: A Foundation for Therapy

EP: 2.From Papillary to CIS: Tailoring NMIBC Treatment

EP: 3.Defining and Managing BCG-Unresponsive NMIBC

Now Viewing

EP: 4.NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up

EP: 5.FDA-Approved Options for High-Risk BCG-Unresponsive NMIBC

EP: 6.An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC

EP: 7.An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC

EP: 8.Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC

EP: 9.Exploring Nadofaragene Firadenovec: Ongoing Trials and Study Designs

EP: 10.Topline Results From Recent NMIBC Trials

Physician Summary:

For patients with initially responsive NMIBC, maintenance therapy is a cornerstone of ongoing disease control, particularly in those with intermediate- or high-risk features. The standard maintenance approach, based on SWOG protocol, typically includes BCG instillations once weekly for 3 weeks at 3, 6, 12, 18, 24, 30, and 36 months following induction. However, schedules may be adjusted based on patient tolerance, risk level, and evolving guidelines.

Surveillance remains critical during and after maintenance therapy. Patients are generally monitored with cystoscopy and urine cytology every 3 to 6 months for the first 2 years, then at increasing intervals thereafter. Imaging and upper tract evaluation may be added depending on risk and clinical findings. Close monitoring ensures early detection of recurrence or progression and guides timely intervention.